Stockreport

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

BioAtla, Inc.  (BCAB) 
PDF CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in [Read more]